ImCheck Therapeutics, a biotech company on the cutting edge of the next wave of immunotherapies against cancer and autoimmune diseases, announced the award of €2 million from Bpifrance to contribute to the development of its most advanced novel cancer immunotherapy program. With this additional financing, ImCheck has obtained a total of €3.7 million in non-dilutive funding since its €20 million Series A in 2017. [...]